-- nab Tumor-Targeting Technology Applied to Docetaxel Injection ...
-- nab Tumor-Targeting Technology Applied to Docetaxel Injection (Taxotere) Increased Activity and Decreased Toxicity in a Pre-clinical Study
-- Importance of SPARC Expression in Tumor Response to Taxanes Described in Patients with Head-and-Neck Cancer
SCHAUMBURG, Ill. & LOS ANGELES--(BUSINESS WIRE)--Apr 4, 2006--American Pharmaceutical Partners, Inc. (NASDAQ:APPX) and American Bioscience Inc. (ABI) today announced the presentation of data at the 97th Annual Meeting of the American Association of Cancer Research (AACR) that further highlights its proprietary nanoparticle albumin-bound (nab(TM)) tumor-targeting technology.
ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particle for injection) (albumin bound) in a pre-clinical dose-ranging study across various tumor models showed improved activity versus solvent-based docetaxel injection (Taxotere(R)). Taxanes (paclitaxel and docetaxel, Taxol(R) and Taxotere, respectively) are among the most widely used chemotherapeutic agents, however conventional forms of these agents cannot be administered without the combination of toxic solvents. Solvents cause significant additional side effects beyond those associated with the chemotherapeutic agent.
Data presented (Poster #5437; Title: Improved effectiveness of ABRAXANE versus Taxotere in multiple different xenografts as a function of HER2 and SPARC status) at AACR investigated the potential of improved safety and activity of ABRAXANE vs. Taxotere (docetaxel injection) in the pre-clinical setting. The dose ranging study found that ABRAXANE was nontoxic up to 120mg/kg. In contrast, Taxotere showed a dose dependent weight loss for 15-50 mg/kg with the maximum tolerated dose at 15 mg/kg. ABRAXANE was more active than Taxotere with demonstrated tumor growth inhibition at 15 mg/kg in four of five models. The study suggests that ABRAXANE, which uses tumor targeting technology, nab(TM), was more effective, or equally effective, at a submaximum tolerated dose (MTD) compared with Taxotere at its MTD in four of five models, concluding that a clinical study of ABRAXANE versus Taxotere was warranted.
ABI's nanoparticle albumin-bound (nab) tumor-targeting technology exploits the natural properties of a human protein, albumin, for drug delivery. By wrapping albumin around active drug and creating particles of approximately 130 nanometers, ABI has found a way to eliminate the need for solvents and deliver higher concentrations of chemotherapy without the solvent-related toxicities compared with solvent-based taxanes. The FDA approval of ABRAXANE validated the nab technology and in a phase three trial, ABRAXANE showed higher tumor response rates and greater safety than Taxol.
A second pre-clinical study (Poster #5438; Title: Enhanced efficacy and safety of nanoparticle albumin-bound nab-docetaxel versus Taxotere) applied nab technology to docetaxel and in pre-clinical models of colon cancer compared nab-docetaxel with Taxotere (docetaxel injection). The study suggested that nab-docetaxel showed significantly greater antitumor activity against colon
This is cache, read story here